Northern Trust Corp lifted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 5.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 112,905 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,599 shares during the quarter. Northern Trust Corp owned 0.97% of ANI Pharmaceuticals worth $5,285,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Texas Permanent School Fund lifted its stake in ANI Pharmaceuticals by 1.9% in the 2nd quarter. Texas Permanent School Fund now owns 5,863 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 111 shares in the last quarter. Prudential Financial Inc. lifted its stake in ANI Pharmaceuticals by 1.4% in the 1st quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock valued at $697,000 after buying an additional 200 shares in the last quarter. Thrivent Financial For Lutherans lifted its stake in ANI Pharmaceuticals by 5.1% in the 1st quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 220 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in ANI Pharmaceuticals by 0.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 54,205 shares of the specialty pharmaceutical company’s stock valued at $2,536,000 after buying an additional 340 shares in the last quarter. Finally, Cadence Capital Management LLC lifted its stake in ANI Pharmaceuticals by 5.7% in the 2nd quarter. Cadence Capital Management LLC now owns 6,397 shares of the specialty pharmaceutical company’s stock valued at $299,000 after buying an additional 345 shares in the last quarter. 56.48% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals, Inc. (NASDAQ ANIP) opened at $63.75 on Friday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals, Inc. has a 12 month low of $42.23 and a 12 month high of $65.81. The firm has a market cap of $723.15, a P/E ratio of 19.12 and a beta of 2.84.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The business had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. During the same period last year, the company posted $1.09 EPS. The business’s revenue was up 25.0% on a year-over-year basis. sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.59 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on the stock. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a research note on Tuesday, November 7th. Canaccord Genuity reaffirmed a “buy” rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $68.25.

COPYRIGHT VIOLATION NOTICE: “ANI Pharmaceuticals, Inc. (ANIP) Stake Raised by Northern Trust Corp” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/18/ani-pharmaceuticals-inc-anip-stake-raised-by-northern-trust-corp.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.